SUZHOU, China, May 29, 2026
Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of a Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, an investigational small interfering RNA (siRNA) therapy designed to treat coronary artery disease (CAD). The regulatory filing marks a significant milestone in the company’s rapidly expanding cardiovascular pipeline and reinforces Ribo’s position as a leading innovator in RNA-based therapeutics targeting thromboembolic diseases. The advancement of RBD1119 into Phase 2 development highlights the growing potential of gene-silencing technologies to address major cardiovascular disorders while offering an improved balance between efficacy and safety compared with conventional antithrombotic therapies.
RBD1119 Expands Ribo’s Leadership in RNA-Based Cardiovascular Medicine
Coronary artery disease remains one of the leading causes of death and disability worldwide, affecting millions of patients and placing enormous pressure on healthcare systems. The disease is driven by the accumulation of atherosclerotic plaque within coronary arteries, increasing the risk of blood clot formation, myocardial infarction, stroke, and other serious cardiovascular complications. Although current treatment strategies rely heavily on antiplatelet agents and anticoagulants, many patients continue to experience thrombotic events despite receiving optimized therapy.
Ribo’s investigational candidate RBD1119 utilizes advanced siRNA technology, which works by selectively silencing disease-related genes involved in thrombosis and cardiovascular risk pathways. By targeting the underlying biological mechanisms responsible for clot formation, the therapy aims to provide long-lasting antithrombotic protection while minimizing the bleeding complications commonly associated with traditional blood-thinning medications.
The company has been actively building one of the industry’s most comprehensive anticoagulation and antithrombotic siRNA pipelines, with additional programs under development for atrial fibrillation and venous thromboembolism (VTE). The Phase 2 CTA submission represents another important step in Ribo’s broader strategy to establish RNA interference technology as a transformative platform for cardiovascular disease management.
Advertisement
Addressing a Major Unmet Need in Coronary Artery Disease
Despite major advances in cardiovascular medicine over recent decades, residual thrombotic risk remains a significant challenge for patients with stable coronary artery disease. Even among individuals receiving standard therapies, including dual antiplatelet treatment and anticoagulation regimens, the risk of recurrent ischemic events remains substantial. Physicians often face a difficult balance between preventing thrombosis and avoiding potentially serious bleeding complications.
The development of RBD1119 seeks to address this critical therapeutic gap. Through targeted gene silencing, the investigational therapy is designed to deliver durable anticoagulant and antithrombotic effects without requiring frequent dosing or exposing patients to the same degree of bleeding risk associated with existing treatments. This differentiated mechanism could potentially improve long-term disease management while reducing treatment-related complications.
Industry experts increasingly view RNA-based medicines as one of the most promising areas of cardiovascular drug development. The success of several approved RNA therapeutics in other disease areas has accelerated interest in applying similar approaches to complex cardiovascular conditions where conventional treatment options remain limited.
Phase 2 Development Signals Growing Momentum for siRNA Therapeutics
The EMA submission demonstrates the continued maturation of Ribo’s clinical development capabilities and reflects growing regulatory confidence in RNA interference technologies. Over the past decade, siRNA therapeutics have evolved from experimental concepts into clinically validated treatment platforms capable of delivering highly specific and durable therapeutic effects.
According to company leadership, advancing multiple cardiovascular siRNA programs simultaneously positions Ribo at the forefront of next-generation anticoagulation research. The company believes that RNA-based therapies may offer a fundamentally different approach to preventing thromboembolic events by targeting disease pathways at the genetic level rather than relying solely on traditional pharmacological inhibition.
If successful, RBD1119 could become an important new treatment option for patients with coronary artery disease who remain at risk of cardiovascular events despite current standard-of-care therapies. The program also strengthens the broader promise of siRNA technology in addressing some of the world’s most prevalent and life-threatening cardiovascular conditions.
As Ribo moves forward with Phase 2 development in Europe, the clinical community will closely monitor the progress of RBD1119. The program represents not only a significant milestone for the company but also a potentially important advancement in the evolution of precision RNA therapeutics for cardiovascular and thromboembolic diseases.
Source: Ribo press release
